Skip to content

Program 1: PRECIZE

PRECIZE: PREdict and CharacterIZE high-risk patients in breast cancer and multiple myeloma

 

Program coordinators:

Pr Caroline Bodet Milin, MD, PhD, nuclear medicine physician at Nantes University Hospital
Dr Eric Letouzé, head of team 8 at CRCI2NA

The integrated research program PRECIZE addresses a crucial medical need to predict and characterize high-risk relapse patients in the era of new therapeutic strategies, specifically in multiple myeloma and breast cancer.

PRECIZE is based on the integration of data from multiple methods (multi-omics) and various scales of observation: from the single cell (omics) to the whole body (imaging), across large clinical trial cohorts (MIDAS, IFM-2022, EPICURE, NEO EPICURE) at the initiation and during treatment, to gain a comprehensive view of the pathology and closely align with the clinical situation. Correlating innovative imaging data with genomic and functional data linked to clinical data will allow us to identify the most important determinants for characterizing high-risk disease. These multimodal predictors will then be applied to a “real-life” cohort to enable rapid evaluation and transfer to clinical practice and patients.

PRECIZE is organized into 4 research axes:

  • WP1: Multimodal imaging, radiomics and AI approaches in MM
    Leads: Diana Mateus, Thomas Carlier
  • WP2 : Phenotype and predictive imaging in MM and BC
    Leads: Caroline Bodet Milin, Mickaël Bourgeois
  • WP3: Multi-omics approach for precision medicine of HR BC
    Leads: Caroline Rousseau, Pascal Jézéquel
  • WP4 : Molecular characterization and multimodal predictor of HR MM
    Leads: Stéphane Minvielle, Cyrille Touzeau

PRECIZE relies on a multidisciplinary consortium involving the medical and research teams of Nantes University Hospital (CHU de Nantes), the ICO, CRCI2NA, LS2N, the Arronax cyclotron, Polytech, and the mathematics laboratories LAREMA and LMJL.